These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9582616)
1. Acute endocrine effects of interleukin-12 in cancer patients. Lissoni P; Rovelli F; Rivolta MR; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G J Biol Regul Homeost Agents; 1997; 11(4):154-6. PubMed ID: 9582616 [TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395 [TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide can modulate immune and endocrine responses during lipopolysaccharide-induced acute inflammation. Bik W; Wolinska-Witort E; Chmielowska M; Baranowska-Bik A; Rusiecka-Kuczalek E; Baranowska B Neuroimmunomodulation; 2004; 11(6):358-64. PubMed ID: 15467350 [TBL] [Abstract][Full Text] [Related]
4. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238 [TBL] [Abstract][Full Text] [Related]
5. Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems. Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E J Biol Regul Homeost Agents; 2005; 19(3-4):141-4. PubMed ID: 16602629 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol. Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779 [TBL] [Abstract][Full Text] [Related]
7. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586 [TBL] [Abstract][Full Text] [Related]
10. [The effect of a single electroconvulsive shock on pituitary-thyroid-adrenal-gonadal axis function in men with severe depression--preliminary report]. Motta E; Ostrowska Z; Kazibutowska Z; Paluch M; Płonka J; Gołba A Psychiatr Pol; 2005; 39(3):469-79. PubMed ID: 16149757 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667 [TBL] [Abstract][Full Text] [Related]
12. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2. Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients. Lissoni P; Barni S; Rovelli F; Crispino S; Fumagalli G; Pescia S; Vaghi M; Camesasca G; Tancini G Tumori; 1991 Jun; 77(3):212-5. PubMed ID: 1862547 [TBL] [Abstract][Full Text] [Related]
14. Hypothalamic-pituitary-end organ function in women with bipolar depression. Rasgon NL; Kenna HA; Wong ML; Whybrow PC; Bauer M Psychoneuroendocrinology; 2007 Apr; 32(3):279-86. PubMed ID: 17317022 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Lissoni P; Bolis S; Brivio F; Fumagalli L Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160 [TBL] [Abstract][Full Text] [Related]
16. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Köller MD; Templ E; Riedl M; Clodi M; Wagner O; Smolen JS; Luger A Ann Rheum Dis; 2004 Dec; 63(12):1677-80. PubMed ID: 15082470 [TBL] [Abstract][Full Text] [Related]
17. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754 [TBL] [Abstract][Full Text] [Related]
18. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288 [TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine features in extreme longevity. Ferrari E; Cravello L; Falvo F; Barili L; Solerte SB; Fioravanti M; Magri F Exp Gerontol; 2008 Feb; 43(2):88-94. PubMed ID: 17764865 [TBL] [Abstract][Full Text] [Related]
20. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia. Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]